Decitabine

An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA.

Also Known As:

2'-Deoxy-5-azacytidine; 5-Aza-2'-deoxycytidine; 5-AzadC; 5-Azadeoxycytidine; 5-Deoxyazacytidine; 5AzadC; AzadC Compound; Dacogen; Decitabine Mesylate; NSC 127716; NSC-127716; 2' Deoxy 5 azacytidine; 5 Aza 2' deoxycytidine; 5 Azadeoxycytidine; 5 Deoxyazacytidine; Compound, AzadC; Mesylate, Decitabine; NSC127716

Networked: 2444 relevant articles (209 outcomes, 399 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Garcia-Manero, Guillermo: 53 articles (01/2022 - 08/2003)
2.	Ravandi, Farhad: 41 articles (01/2022 - 03/2003)
3.	Kantarjian, Hagop: 36 articles (12/2021 - 03/2003)
4.	Kantarjian, Hagop M: 35 articles (12/2021 - 08/2003)
5.	Lübbert, Michael: 31 articles (04/2022 - 10/2002)
6.	Jabbour, Elias: 24 articles (01/2021 - 12/2005)
7.	Saunthararajah, Yogen: 23 articles (09/2021 - 01/2003)
8.	Issa, Jean-Pierre J: 23 articles (10/2017 - 03/2004)
9.	Borthakur, Gautam: 20 articles (01/2022 - 02/2007)
10.	Cortes, Jorge: 20 articles (01/2021 - 08/2003)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/01/2019 - "Acquired persistently complete remission by decitabine-based treatment for acute myeloid leukemia with the MLL-SEPT9 fusion gene." 07/01/2006 - "Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine." 12/01/2021 - "This study investigates efficacy of decitabine and priming regimen in treating newly diagnosed acute myeloid leukemia with myelodysplasia related changes (AML-MRC) and elderly AML. " 06/01/2020 - "To study the efficacy of small dose HAG combined with decitabine regimen in the treatment of elderly patients with acute myeloid leukemia (AML). " 02/01/2010 - "Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia."
2.	Neoplasms (Cancer) 03/01/2004 - "We conclude that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses." 01/01/2022 - "The innovative synergistic therapeutic strategy of decitabine and TCR-T cells for the CRC with MSS may be also effective in the treatment of other epithelial malignancies. " 01/01/2014 - "Based on these mechanisms, low-dose decitabine combined with chemoimmunotherapy may be a new treatment option for patients with refractory advanced tumors. " 12/01/2020 - "However, few studies have added decitabine to myeloablative conditioning regimens for UCBT in patients with haematological malignancies not in remission. " 01/01/2018 - "Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer."
3.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/01/2017 - "Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome." 12/01/2016 - "Despite recent advances in the treatment of myelodysplastic syndrome (MDS), single-agent clinical effects remain unsatisfactory, and decitabine monotherapy is also associated with a relatively low rate of complete remission. " 12/01/2021 - "To investigate the efficacy of high-risk myelodysplastic syndrome (MDS) patients treated by different doses of decitabine (DAC) and its safety. " 10/01/2011 - "Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement." 07/01/2014 - "Decitabine, a demethylating drug, is the first-line treatment for myelodysplastic syndromes and gains better overall survival, which is based on epigenetic mechanism. "
4.	Leukemia 01/01/2008 - "5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation, is an effective agent for the treatment of leukemia. " 01/01/2019 - "Drug loading into nanocarriers of 27.45±0.05 nm was 5.8±0.5 mg/mL. The stability of decitabine was improved and its activity on leukemia cells was not altered. " 10/02/2016 - "In this study, we investigated the cytotoxic effects and epigenetic changes associated with the combination of DMC and the DNMT inhibitor decitabine (DAC) in primary leukemia samples and cell lines. " 12/01/2013 - "In this study, we aimed to show that decitabine could induce specific autologous CTLs against some mouse CTAs in leukemia cells in vitro and in vivo. " 11/01/2013 - "In the present study, following treatment with a demethylating agent, decitabine, NXF2 expression was detected in the majority of the NXF2‑negative acute leukemia cell lines, but not in healthy donor samples. "
5.	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 04/01/2008 - "Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)." 01/01/2023 - "We conducted a randomized phase III trial comparing decitabine (DAC) and HY in advanced myeloproliferative chronic myelomonocytic leukemias (CMML). " 10/06/2011 - "Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial." 01/01/2018 - "A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia." 05/01/2015 - "Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia."

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	Azacitidine (5 Azacytidine)
3.	Cytarabine (Cytosar-U)
4.	Methyltransferases
5.	Decitabine
6.	venetoclax
7.	Granulocyte Colony-Stimulating Factor (G-CSF)
8.	A-Form DNA (A-DNA)
9.	trichostatin A (A 300)
10.	Aclarubicin

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Hematopoietic Stem Cell Transplantation
4.	CAG protocol
5.	Immunotherapy